Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management

Company Overview - Altamira Therapeutics is focused on developing and commercializing RNA delivery technology for targets beyond the liver, with a notable emphasis on peptide-based nanoparticle technologies [9] - The company is developing AM-125, an intranasal formulation of betahistine, to improve bioavailability and provide treatment options for patients in the US [5][15] - Altamira is also working on strategic partnerships or divestments of its legacy assets, including AM-125, as part of a pivot towards RNA delivery technology [5][7] Industry Context - Benign paroxysmal positional vertigo (BPPV) is the most common type of vertigo, accounting for 17% to 42% of all diagnosed cases, with healthcare costs in the US approaching $2 billion annually [12] - Residual dizziness occurs in 31% to 61% of BPPV patients, significantly affecting their quality of life and daily activities [11][12] - Betahistine is considered a standard treatment for dizziness and vertigo, with its oral formulation approved in approximately 115 countries, although it is not available in the US [5][14] Treatment Insights - The combination of physical repositioning procedures and betahistine treatment has shown a significantly greater reduction in dizziness handicap compared to the procedure alone, with a p-value of 0.001 [5][10] - AM-125 has demonstrated 5-to-29 times higher bioavailability than orally administered betahistine, which may enhance treatment efficacy for vestibular disorders [15] - The company aims to test AM-125 specifically for BPPV, as treatment for this condition is a primary indication for betahistine [7]